Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,386 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Gram-Negative Bacterial Infections
Interventions
Minocycline IV
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Las Vegas, Nevada + 3 more
Conditions
Shigella
Interventions
ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
Biological · Other
Lead sponsor
Eveliqure Biotechnologies GmbH
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cryptogenic Cirrhosis, Cryptogenic Chronic Hepatitis
Interventions
skin punch biopsy collection, Blood collection, Urine sample collection
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
Omadacycline, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more
Conditions
Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection
Interventions
AEMCOLO (Rifamycin SV MMX)
Drug
Lead sponsor
Bradley Connor
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Skin Immunity Sample Collection Involving Blisters and Biopsies

NCT03921515
Conditions
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Interventions
Blister induction, Skin Biopsies
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

LMN-101 in a Campylobacter Human Challenge Model

NCT04182490
Conditions
Campylobacter Infections
Interventions
LMN-101, Placebo
Biological · Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

NCT01812889
Conditions
Vaginal Infection
Interventions
TOL-463 Vaginal ovule, TOL-463 Vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers

Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin

NCT02348424
Conditions
Gonorrhoea
Interventions
Solithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pneumococcal Disease
Interventions
20vPnC, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,710 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
21
States / cities
Anaheim, California • Sacramento, California • San Jose, California + 16 more
Conditions
Bacterial Infections
Interventions
11C-Trimethoprim
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Spontaneous Bacterial Peritonitis
Interventions
Dextran 70, human albumin
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hidradenitis Suppurativa
Interventions
NovoSorb® BTM, Human Cadaveric Allograft
Device
Lead sponsor
Joseph M. Still Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Augusta, Georgia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

NCT01048697
Conditions
Obesity, Tuberculosis
Interventions
Ethambutol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
23
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational

Hidradenitis Suppurativa Mail Survey

NCT03572738
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
67 participants
Timeline
2018 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I STEBVax in Healthy Adults

NCT00974935
Conditions
Toxic Shock Syndrome Staphylococcal
Interventions
Aluminum hydroxide, STEBVax vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Conditions
Tinea Capitis
Interventions
Scalp Brushing
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 5 Years
Enrollment
446 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Interventions
vaginal cooling device
Device
Lead sponsor
Coologics, Inc
Industry
Eligibility
22 Years to 49 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more
Conditions
Onychomycosis
Interventions
Organogel of naftifine, 2%, Organogel of terbinafine, 2%, Organogel of naftifine, 6%, Organogel of terbinafine, 6%
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Birmingham, Alabama • Tucson, Arizona • Miami Beach, Florida + 2 more
Completed No phase listed Observational

CTTI Risk Factors for HABP/VABP Study

NCT02689531
Conditions
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
7,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
Fisons
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York